Skip to main content

Thermo Fisher Scientific (TMO) Stock Price & Market Analysis

TMO · NYSE · Diagnostics & Research

Market closedLatest regular-session print

$678.60

▲ +$3.60(+0.53%)4:00 PM ET - vs previous close

Quote as of Sep 28, 2026, 4:00 PM EDT

NYSE market is closed. Showing the latest available regular-session trade from Sep 28, 2026, 4:00 PM EDT.

Yahoo Finance · latest regular-session print · as of Sep 28, 2026, 4:00 PM EDT · delay not stated · current source

Last session79%
$664.23L Sep 28 '26$682.43H Sep 28 '26
52-week98%
$435.27L May 18 '26$682.98H Sep 24 '26
Long-term rangesSince first print
Since first print(2000-09-28)99%
$13.53L Jul 24 '02$682.98H Sep 24 '26

Loading price chart…

Session market context

TMOStock · vs previous close
↑ +0.53%
QQQNasdaq-100 ETF
↓ -1.07%

TMO outperformed the sector by 1.60 percentage points.

Price comparisons describe market context; they do not establish the cause of a move.

Data freshness

PriceAt closeLast traded

Fundamentalsevery 1 hrProvider checked

Analystevery 12 hrProvider checked

NewsTECHi refresh every 15 minLatest item

Loading upcoming events…

Company · Profile

About Thermo Fisher Scientific (TMO)

Sector, leadership, and how Thermo Fisher Scientific earns its revenue.

Thermo Fisher Scientific

NYSE · TMO · US

Thermo Fisher Scientific Inc. provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services internationally. It operates through four segments: Life Sciences Solutions, Analytical Instruments, Specialty Diagnostics, and Laboratory Products and Biopharma Services. The Life Sciences Solutions segment includes reagents, instruments, and consumables for biological and medical research; discovery and production of drugs and vaccines; and diagnosis of infections and diseases. Its Analytical Instruments segment provides instruments, consumables, software, and services for pharmaceutical, biotechnology, academic, government, environmental, and other research and industrial markets, as well as clinical laboratories. The Specialty Diagnostics segment offers clinical diagnostics products, such as liquid ready-to-use and lyophilized immunodiagnostic reagent kits, calibrators, controls, protein detection assays, and instruments; immunodiagnostic offerings comprising developing, manufacturing, and marketing of complete blood-test systems for the clinical diagnosis and monitoring of allergy, asthma and autoimmune diseases; microbiology offerings, such as dehydrated and prepared culture media, collection and transport systems, instrumentation and consumables to detect pathogens in blood, diagnostic and rapid direct specimen tests, quality-control products, and associated products; transplant diagnostics products, including human leukocyte antigen typing and testing for the organ transplant market; and healthcare market channel offerings. Its Laboratory Products and Biopharma Services segment provides laboratory products, research and safety market channel, and pharma services and clinical research. Thermo Fisher Scientific Inc. was founded in 1956 and is headquartered in Waltham, Massachusetts.

Sector
Healthcare
Industry
Diagnostics & Research
Headquarters
Waltham, MA, United States
Country
US
Founded
1980
Employees
125,000
CEO
Mr. Marc N. CasperCompany leadership source
Exchange
NYSE
Business model & operating evidence

Company website ↗

AI business exposure

Revenue exposure
AI-specific revenue is not separated in the available company statements.
Capital-spending dependency
No reviewed quantitative dependency model is available.
Compute role
See the sourced business description; AI labels do not establish compute revenue.
Platform examples
An exhaustive, consistently defined product inventory is unavailable.
Ecosystem links
Supplier and customer links require reviewed disclosures.

Narrative versus numbers

Demand is expanding

Insufficient evidence: Unavailable

Quarterly revenue growth year over year; company-wide, not exclusively AI. · Company financial statements · date unavailable

Growth produces accounting profit

Insufficient evidence: Unavailable

Net margin. A positive figure supports profitability, not necessarily cash generation. · Company financial statements · date unavailable

The business generates cash after investment

Insufficient evidence: Unavailable

Latest available free cash flow; period-specific, not a forecast. · Company financial statements · date unavailable

These are explicit tests of individual claims, not an overall bull/bear rating. Demand growth can coexist with valuation, concentration and financing risk.

Operating measures

Comparable operating figures are unavailable for this company.

Leadership

CEO: Mr. Marc N. Casper

Source: Yahoo Finance · 2026-09-29T10:23:11.545Z

Ownership filings and insider activity
Competitors & comparisons

Loading competitor research…

Loading fund exposure…

Governance & sustainability

Dated environmental and governance disclosures are not available in this dataset. TECHi does not infer an ESG rating from profitability, volatility, headcount or executive biographies.

Find proxy statements and annual reports

Read TMO news & coverage
All data sources

Search the dated figures used for this view. Each entry identifies its units, reporting period and calculation status.

Browse all companies and funds
Research tools
US market hours

Regular hours: 9:30 AM–4:00 PM America/New_York

Next open: Checking…

Exchange calendar includes scheduled holidays and early closes. Extended-session prices appear separately only when supplied by the quote source.